JAC Advance Access originally published online on May 18, 2006
Journal of Antimicrobial Chemotherapy 2006 58(1):76-84; doi:10.1093/jac/dkl182
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach
1 Microbiology Laboratory, Department of Biomedical Sciences, University of Trieste I-34127 Trieste, Italy 2 Department of Pharmaceutical Sciences, University of Trieste I-34127 Trieste, Italy 3 Molecular Simulation Engineering (MOSE) Laboratory, Department of Chemical Engineering, University of Trieste I-34127 Trieste, Italy
Received 23 January 2006; returned 22 February 2006; revised 12 April 2006; accepted 18 April 2006
*Corresponding author. Tel: +39-40-5587187; Fax: +39-40-351668; E-mail: banfi{at}dsb.units.it
Objectives: To synthesize new antimycobacterial and antifungal drugs that act by binding to sterol 14
-demethylase (14DM) and to characterize the drug–target protein interactions using computer-based molecular simulations.
Methods: Different series of imidazole and triazole derivatives having an azomethine linkage to pyridine 2-carboxamidrazone were designed and synthesized. Molecular dynamic simulations of the sterol 14DM (a mixed-function oxidase involved in sterol synthesis in eukaryotic and prokaryotic organisms) complexed with new azole derivatives have been performed to both qualify and quantify the protein–ligand interactions. MICs of the compounds were evaluated by reference assay and by the recently developed Microdilution Resazurin Assay (MRA).
Results: Halogenated derivatives showed good activity, with an MIC90 of 1 mg/L against 33 Candida spp. clinical strains; most compounds also had inhibitory activity against Mycobacterium tuberculosis reference and clinical strains, with MICs in the range 4–64 mg/L. Molecular modelling investigations showed that the active new compounds may interact at the active site of both the fungal and the mycobacterial cytochrome P450-dependent sterol-14-demethylase and that the calculated binding free energy values are in agreement with the corresponding MIC values.
Conclusions: The combined experimental and computational approach can be helpful in targeted drug design, thus yielding valuable information for the synthesis and prediction of activity of a second generation of inhibitors.
Keywords: antitubercular , molecular modelling , pyridinecarboxamidrazone-azole derivatives
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. M. Podust, H. Ouellet, J. P. von Kries, and P. R. Ortiz de Montellano Interaction of Mycobacterium tuberculosis CYP130 with Heterocyclic Arylamines J. Biol. Chem., September 11, 2009; 284(37): 25211 - 25219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sheng, Z. Miao, H. Ji, J. Yao, W. Wang, X. Che, G. Dong, J. Lu, W. Guo, and W. Zhang Three-Dimensional Model of Lanosterol 14{alpha}-Demethylase from Cryptococcus neoformans: Active-Site Characterization and Insights into Azole Binding Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3487 - 3495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Eddine, J. P. von Kries, M. V. Podust, T. Warrier, S. H. E. Kaufmann, and L. M. Podust X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14{alpha}-Demethylase (CYP51) J. Biol. Chem., May 30, 2008; 283(22): 15152 - 15159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ouellet, L. M. Podust, and P. R. O. de Montellano Mycobacterium tuberculosis CYP130: CRYSTAL STRUCTURE, BIOPHYSICAL CHARACTERIZATION, AND INTERACTIONS WITH ANTIFUNGAL AZOLE DRUGS J. Biol. Chem., February 22, 2008; 283(8): 5069 - 5080. [Abstract] [Full Text] [PDF]
|
|